Drugs / MK-1293
MK-1293
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02059174 | Feb 2014 → Mar 2015 | type 1 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02059187 | Feb 2014 → Mar 2015 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT02059161 | Oct 2013 → May 2015 | type 1 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1293 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02059161 ↗ |
| Known as | insulin glargine | “AIMS: MK-1293 is an insulin glargine that has an amino acid sequence identical to that of Lantus, the originator insulin glargine.” PMID 28817223 ↗ Sep 20172“MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks.” NCT02059187 ↗ “MK-1293 insulin glargine (Mk-Gla; 100 U/mL)” PMID 29766635 ↗ Jun 2018 |
| Known as | Mk-Gla | “AIM: To compare the efficacy and safety of MK-1293 insulin glargine (Mk-Gla) and Lantus (Sa-Gla) in people with type 2 diabetes mellitus (T2DM).” PMID 29761615 ↗ Jun 20181“MK-1293 insulin glargine (Mk-Gla; 100 U/mL)” PMID 29766635 ↗ Jun 2018 |
| Modality | Protein / enzyme biologic | “MK-1293 insulin glargine (Mk-Gla; 100 U/mL)” PMID 29766635 ↗ Jun 2018 |
| Route | Subcutaneous | “MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks.” NCT02059161 ↗ |